Comparing SG&A Expenses: Agios Pharmaceuticals, Inc. vs Travere Therapeutics, Inc. Trends and Insights

Biotech Giants: SG&A Expense Trends from 2014 to 2023

__timestampAgios Pharmaceuticals, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 20141912000059644696
Thursday, January 1, 20153599200079541000
Friday, January 1, 20165071400098015000
Sunday, January 1, 201771124000103958000
Monday, January 1, 2018114145000103654000
Tuesday, January 1, 2019132034000128951000
Wednesday, January 1, 2020149070000135799000
Friday, January 1, 2021121445000149883000
Saturday, January 1, 2022121673000220206000
Sunday, January 1, 2023119903000265542000
Monday, January 1, 2024156784000
Loading chart...

Unveiling the hidden dimensions of data

SG&A Expenses: A Tale of Two Biotech Companies

In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Agios Pharmaceuticals, Inc. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, Travere Therapeutics consistently outpaced Agios in SG&A spending, with a notable 123% increase from 2014 to 2023. Agios, on the other hand, saw a 526% rise in the same timeframe, reflecting its strategic investments in growth and development.

By 2023, Travere's SG&A expenses reached approximately 2.66 times that of Agios, highlighting its aggressive expansion strategy. This trend underscores the differing approaches of these companies in navigating the biotech landscape. As the industry evolves, understanding these financial dynamics offers valuable insights into the operational strategies of leading biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025